AbbVie (ABBV) Notes Payables (2012 - 2025)

AbbVie has disclosed Notes Payables across 14 years of filings, most recently posting $2.5 billion for Q4 2025.

• In Q4 2025, Notes Payables changed N/A year-over-year to $2.5 billion; the TTM figure through Dec 2025 stood at $2.5 billion (changed N/A YoY), while the FY2025 annual figure was $2.5 billion, changed N/A from the prior year.
• Notes Payables declined to $2.5 billion in Q4 2025, from $3.8 billion in the prior quarter.
• Over the last five years, Notes Payables for ABBV reached as high as $3.8 billion in Q3 2025 and fell as low as $1.0 million in Q4 2022.
• The 5-year median for Notes Payables is $14.0 million (2021), against an average of $665.6 million.
• Annual changes were most pronounced in 2022 — Notes Payables sank 92.86% — and 2025, when it surged 53000.0%.
• A 5-year view of Notes Payables shows it stood at $14.0 million in 2021, then slumped by 92.86% to $1.0 million in 2022, then jumped by 100.0% to $2.0 million in 2023, then soared by 50.0% to $3.0 million in 2024, then jumped by 83200.0% to $2.5 billion in 2025.
• According to Business Quant data, Notes Payables over the past three periods registered $2.5 billion, $3.8 billion, and $2.0 billion for Q4 2025, Q3 2025, and Q2 2025 respectively.